Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2

by LoRusso, Patricia, Venkatakrishnan, Karthik, Chiorean, E. Gabriela, Noe, Dennis, Wu, Jing-Tao, Sankoh, Serap, Corvez, Maria, Sausville, Edward A.
Published 2013

Contribution of Environment and Genetics to Pancreatic Cancer Susceptibility

by Hocevar, Barbara A., Kamendulis, Lisa M., Pu, Xinzhu, Perkins, Susan M., Wang, Zheng-Yu, Johnston, Erica L., DeWitt, John M., Li, Lang, Loehrer, Patrick J., Klaunig, James E., Chiorean, E. Gabriela
Published 2014

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

by Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Wee Ma, Wen, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Shiansong Li, Jack, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Published 2016

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

by Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Ma, Wen Wee, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Li, Jack Shiansong, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Published 2016